Theranostics of Neuroendocrine Tumors

Article written by the clinicians who developed the concept of "Theranostics" at Zentralklinik Bad Berka, Bad Berka, Germany

AUTHORS: Sze Ting Lee, Harshad R. Kulkarni, Aviral Singh and Richard P. Baum

SUMMARY: Somatostatin receptor positron emission tomography/ computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life

? 2017 S. Karger GmbH, Freiburg